We investigated the effect of fish oil (FO) supplementation on tumor growth, cyclooxygenase 2 (COX-2), peroxisome proliferator-activated receptor gamma (PPARc), and RelA gene and protein expression in Walker 256 tumor-bearing rats. Male Wistar rats (70 days old) were fed with regular chow (group W) or chow supplemented with 1 g/kg body weight FO daily (group WFO) until they reached 100 days of age. Both groups were then inoculated with a suspension of Walker 256 ascitic tumor cells (3610 7 cells/mL). After 14 days the rats were killed, total RNA was isolated from the tumor tissue, and relative mRNA expression was measured using the 2 -DDCT method. FO significantly decreased tumor growth (W=13.18±1.58 vs WFO=5.40±0.88 g, P,0.05). FO supplementation also resulted in a significant decrease in COX-2 (W=100.1±1.62 vs WFO=59.39±5.53, P,0.001) and PPARc (W=100.4±1.04 vs WFO=88.22±1.46, P,0.05) protein expression. Relative mRNA expression was W=1.06±0.022 vs WFO=0.31±0.04 (P,0.001) for COX-2, W=1.08±0.02 vs WFO=0.52±0.08 (P,0.001) for PPARc, and W=1.04±0.02 vs WFO=0.82±0.04 (P,0.05) for RelA. FO reduced tumor growth by attenuating inflammatory gene expression associated with carcinogenesis.
Introduction
Several studies have reported the anti-inflammatory properties of n-3 polyunsaturated fatty acids (PUFAs), their involvement in the prevention of some chronic diseases, and their effects on cancer (1, 2) . Changes in dietary fatty acid consumption, particularly in Western diets, cause an increase in the n-6:n-3 PUFA ratio. This change leads to unbalanced production of eicosanoids, which has been associated with the development of inflammatory conditions (2, 3) . We previously reported that dietary supplementation with fish oil (FO), rich in n-3 PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), reduced tumor growth and cachexia in Walker 256 tumor-bearing rats (4) (5) (6) . FO supplementation significantly enhanced the tumor content of n-3 PUFAs, with diminution of the n-6:n-3 ratio and reduction of cyclooxygenase-2 (COX-2) expression and prostaglandin E 2 (PGE 2 ) concentration in the plasma. These changes were associated with increased apoptosis and lipoperoxidation in the tumor tissue (6) . Although all these findings might explain many of the anti-tumor actions of n-3 PUFA, eicosanoidindependent actions including EPA and DHA effects on transcription factors regulating inflammatory gene expression cannot be ruled out. It has been suggested that the high amount of n-3 PUFAs or shift in the n-6:n-3 ratio may attenuate the expression of important genes related to inflammation (3). n-3 PUFA can activate several transcription factors through signaling pathways that alter the expression of inflammatory genes (7, 8) . So far, the molecular mechanisms involved are not fully understood, and it has been proposed that multiple mechanisms contribute to the effects of n-3 PUFA on cancer (9) .
COX-1 and COX-2 are enzymes that catalyze the production of prostaglandins and thromboxanes from arachidonic acid (1) . COX-1 is distributed and constitutively expressed in most cells and tissues. In contrast, COX-2 mRNA can be induced by inflammatory and Correspondence: L.C. Fernandes, Departamento de Fisiologia, Universidade Federal do Parana´, 81530-900 Curitiba, PR, Brasil. Fax: + +55 41-3361-1714. E-mail: lcfer@ufpr.br proliferative stimuli. Although COX-2 induction is required during pathophysiological states, constitutive COX-2 activity is detected in brain, kidney, and the female reproductive tract (10) .
Peroxisome proliferator-activated receptor gamma (PPARc) is a ligand-activated transcription factor belonging to the nuclear hormone receptor family (PPARs a, b/d, and c) (1). Some studies have suggested that PPARc regulates signal transduction pathways that lead to cell differentiation and inhibition of cell proliferation in several groups of carcinoma. In addition, it may play a role in the inflammatory response (1, 11) .
The nuclear factor kappa B (NFkB) family includes members of the Rel family, including p50 (NFkB1), p52 (NFkB2), c-Rel, v-Rel, RelA (p65), and RelB. Their activation has been linked to a broad variety of proinflammatory and proangiogenic stimuli (12) . In addition, NFkB has been associated with inflammation and immunity in cancer development (7) .
Here we hypothesize that tumor growth reduction shown in Walker 256 tumor-bearing rats supplemented with FO is also regulated at the gene level. The objective of this study was to investigate the effects of FO supplementation on COX-2, PPARc, and RelA gene expression in Walker 256 tumor-bearing rats.
Material and Methods

Animals and study design
All experimental procedures were carried out in accordance with the ethical principles established by the Experimental Brazilian Council (COBEA) and approved by the local Ethics Animal Experiment Committee (certificate number 344). Male, 70-day-old Wistar rats were housed under controlled temperature (236C), humidity (50±5%) and a 12:12-h light-dark cycle, and received a regular chow diet (Nutrilab CR1, Nuvital Nutrients Ltda., Brazil) ad libitum. The rats were divided into two groups, one was fed regular chow only (W group) and the other was fed the same regular chow supplemented with oral FO (WFO group). FO composition of the supplement was determined by HPLC to contain (% fatty acid): 4.8% lauric, 9.9% miristic, 15% palmitic, 1.9% stearic, 17% palmitoleic, 10.6% oleic, 11.6% linoleic, 0.7% arachidonic, 23.8% EPA, and 19.8% DHA. The FO capsules were kindly donated by the Herbarium Foundation for Health and Research (Curitiba, PR, Brazil). The WFO group received the oil at a dose of 1 g/kg body weight daily, given orally using a microliter pipette, until they reached 100 days of age. All animals were then inoculated in the right flank with a 1-mL sterile suspension of Walker 256 ascitic tumor cells (3610 7 cells/mL). On the 14th day after tumor inoculation, they were killed, the tumor mass was removed, and different samples of the same tumor were used for experimental analyses.
Immunoblotting
Protein concentration in the tumor tissue was determined using the Bradford method. Tumor tissue samples (100 mg) were homogenized in radioimmune precipitation assay lysis buffer, and samples (45 mg) were loaded to a 10% SDS polyacrylamide gel for electrophoresis and then transferred to nitrocellulose membranes using a semi-dry blotter apparatus (Bio-Rad, USA). The membranes were incubated overnight at 46C with the following individual antibodies: anti-COX-2 (72 kDa), anti-PPARc (67 kDa), anti-RelA (p65; 65 kDa), and anti-b-actin (43 kDa) at a 1:1000 dilution (Santa Cruz Biotechnology, USA), and then for 2 h with a secondary antibody-conjugated rabbit horseradish peroxidase (Pierce, USA) at a 1:6000 dilution. The West Pico Chemoluminescent substrate (Super Signal System Pierce, USA) was used, and membranes were exposed to Kodak film before development. The resulting bands were analyzed and quantified by the Image J 1 software (USA), with anti-b-actin as a loading control.
Quantitative real-time PCR (qPCR)
Fresh tumor tissue samples (100 mg) were homogenized and total RNA was isolated using Trizol Reagent (Invitrogen, USA) according to the manufacturer's instructions. RNA concentration and purity were checked with a spectrophotometer (Nanodrop ND 1000, Thermo Scientific, USA). RNA samples with 260/280 and 260/230 nm adsorbance ratios .1.9 were used. The integrity of total RNA was measured by 0.8% agarose gel electrophoresis. Reverse transcription was performed with the Improm II RT System (Promega, USA) according to the manufacturer's protocol. qPCRs were performed in Rotor Gene 6000 (Qiagen, USA) using SYBR Green Mix, following the manufacturer's instructions. PCRs were performed with cDNA samples (5 ng) in triplicate under the following conditions: 956C for 5 min, followed by 35 cycles of (956C for 15 s, 606C for 15 s, and 726C for 15 s). The primers were designed following criteria for real-time PCR and were synthesized by Prodimol, Brazil. The sequences were as follows: 59-CAGGCCAGACTTTGTTGGAT-39 (sense) and 59-CCACTTTCGCTGATGACAC-39 (antisense) 116 bp for the hypoxanthine-guanine phosphoribosyltransferase (HPRT) reference gene; 59-ATCAGGTCATCGGTGGA GAG-39 (sense) and 59-GCACCAGACCAAAGACTTCC-39 (antisense) 126 bp for COX-2; 59-GCCCTTTGGTGACTTT ATGG-39 (sense) and 59-GGCGGTCTCCACTGAGAATA-39 (antisense) 119 bp for PPARc; and 59-ACTTGCCAGAC ACAGACGAT-39 (sense) and 59-GGGTTCAGTTGGTC CATTG-39 (antisense) 145 bp for RelA. Validation of the reference gene (HPRT) and the amplification efficiencies of targets and reference were performed (13); the fold-change for each sample was analyzed by the 2 -DDCT method.
Statistical analysis
Data are reported as means±SE. Statistical analysis was performed with the two-tailed Student t-test using the Fish oil reduces Walker 256 tumor growth at the gene levelPrism Software (GraphPad, USA). The value P,0.05 was taken to indicate statistical significance.
Results
We examined the effect of FO supplementation on tumor growth and protein and relative mRNA expression of COX-2, PPARc, and RelA in tumor tissue from Walker 256 tumor-bearing rats. FO supplementation resulted in a significant decrease (2.4-fold) in tumor weight in the WFO group compared with the W group (W=13.18±1.58 vs WFO=5.40±0.88 g; P,0.05). Protein expression of COX-2 and PPARc in tumor tissue from rats fed regular chow (W) and FO supplemented are shown in Figure 1 . FO supplementation resulted in significant decreases in COX-2 (P,0.001) and in PPARc (P,0.05) expression. The change in RelA protein expression was not significant in the WFO group compared to the W group (data not shown). FO supplementation also resulted in significant decreases in the relative expression of mRNA in tumor tissue (Figure 2 ) of 3.4-fold for COX-2 (P,0.001), 2-fold for PPARc (P,0.001), and 1.2-fold for RelA (P,0.05) in the WFO compared to the W group.
Discussion
Our previous research demonstrated that FO supplementation decreases tumor growth and cancer cachexia in Walker 256 tumor-bearing rats (4-6). Several mechanisms for suppression of tumor growth in Walker 256 tumor-bearing rats by n-3 PUFA have been proposed. The effects of n-3 PUFAs on both cell proliferation and apoptosis are exerted through decreases in PGE 2 production by the COX-2 pathway (6). It has also been shown that a high level of COX-2 induces production of proangiogenic factors in many cancer cells (14) . COX-2 is believed to exert tumor-promoting effects in regulation of the cell survival and signaling pathways that are involved with tumor cell initiation, transformation, invasiveness, and metastasis (15, 16) . It has also been shown that n-3 PUFA has anti-angiogenic and anti-inflammatory effects by attenuation of important molecules, such as COX-2, PGE 2 , and the NFkB family (14) .
The mechanisms that explain, in part, the antiinflammatory effects of n-3 PUFA are related to the decrease in expression of genes related to inflammation, including NFkB, proinflammatory cytokines, and genes involved in eicosanoid synthesis (7, 17) . Studies of FO supplementation in healthy humans suggest that a shift in the n-6:n-3 PUFA ratio is likely to affect inflammatory responses, which may be related to regulation of expression of signal transduction genes (8) . Dietary supplementation with EPA and DHA can change the gene expression profiles of mononuclear cells, decreasing the expression of genes involved in inflammation and atherogenic pathways, eicosanoid synthesis, and hypoxia signaling (17) . It has been reported that PPARs are involved in the beneficial effects of n-3 PUFA leading to gene expression via PPAR activation (1) . Studies of human gastric cancer showed upregulation of PPARc, suggesting its participation in gastric carcinogenesis (11) . Furthermore, it has been suggested that n-3 PUFA is also related to microRNA expression, but the mechanisms remain unknown (18) .
Some important steps should be followed in experimental protocols to analyze relative gene expression using the 2 -DDCT method. The efficiency of target and reference gene amplification as well as the selection of a suitable internal control gene should be validated to avoid inconsistent results (13, 19) . Tumor growth reduction from FO-supplemented rats was accompanied by a significant decrease in the protein and mRNA expression of COX-2 and PPARc as well as in mRNA expression of RelA, but the change in the RelA protein was not significant. The disagreement between mRNA and protein expression is due to the complex mechanisms of gene expression control that include the regulation of the genetic code and the co-and post-translational modifications (19) . Upregulation of PPARc expression is frequent in a variety of malignant tumors. However, its exact role in tumor cell growth is still unclear. PPARs are transcription factors that regulate gene expression and act as intracellular receptors by binding lipid molecules, such as n-3 PUFA. It is probable that n-3 PUFA acts as a transducing signal. However, it is not possible to relate the level of expression to the activity of PPARc. In this study, we suggest that PPARc could be the link between n-3 PUFA and tumor growth. Further studies are necessary to determine the relationship of n-3 PUFA with other genes involved in cell proliferation of tumors as well as cell death.
It has been suggested that multiple molecular mechanisms may contribute to the protective effects of n-3 PUFA against cancer, with its pleiotropic action becoming more evident (9) . Although the molecular mechanisms involved in mRNA regulation are not fully understood, our data suggest that FO may exert its effects by attenuating the expression of inflammatory genes that are associated with carcinogenesis. To our knowledge, this is the first report describing gene expression of COX-2, PPARc, and RelA in Walker 256 tumor-bearing rats supplemented with FO.
